Georgios Ntentas
BSc, MSc, DPhil
Senior radiotherapy physicist
Georgios is a clinical-academic radiotherapy physicist whose work focuses on the early and late effects of cancer treatment, particularly radiation-related cardiovascular toxicity and second cancers. His research integrates radiotherapy physics and medical imaging with epidemiology and population health methods to inform survivorship care, risk stratification and personalised treatment approaches.
In addition to his work in late effects and survivorship, Georgios leads and contributes to research in innovation and advanced technologies in radiotherapy. This includes the use of AI to improve access to radiotherapy in low- and middle-income countries, as well as novel clinical applications such as blood-sparing radiotherapy and cardiac radio-ablation for ventricular tachycardia. His work also includes dose and image-quality optimisation in radiotherapy imaging.
Alongside his research, Georgios contributes to academic leadership and capacity building through his roles in national and international professional networks. He is a member of the Physics Committee of the European Society for Radiotherapy and Oncology (ESTRO), supervises doctoral students, and serves as a peer reviewer for leading journals.
Georgios holds a DPhil in Population Health from the University of Oxford, MSc degrees in Clinical Sciences and Medical Physics from King’s College London and the University of Surrey, a Postgraduate Diploma in Leadership and Management in the Healthcare Sciences from the University of Manchester, and a BSc in Physics from Aristotle University of Thessaloniki.
Recent publications
Estimated Doses to the Heart, Lungs and Oesophagus and Risks From Typical UK Radiotherapy for Early Breast Cancer During 2015-2023.
Journal article
Holt F. et al, (2024), Clin Oncol (R Coll Radiol), 36, e322 - e332
Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Journal article
Jones DA. et al, (2023), Clin Oncol (R Coll Radiol), 35, 301 - 310
Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection.
Journal article
Ntentas G. et al, (2022), Int J Radiat Oncol Biol Phys, 112, 913 - 925
Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry.
Journal article
Jones DA. et al, (2022), Blood Adv, 6, 909 - 919
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
Journal article
Cutter DJ. et al, (2021), J Clin Oncol, 39, 3591 - 3601
